Keros Therapeutics (KROS) EBT (2019 - 2026)

Keros Therapeutics (KROS) has reported EBT for 8 consecutive years, with -$28.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBT rose 12.78% year-over-year to -$28.7 million; the trailing twelve-month figure through Jun 2026 stood at -$95.3 million (down 454.38% YoY), and the FY2025 full-year result was $91.9 million, up 149.13% from the prior year.
• EBT retreated to -$28.7 million in Q2 2026 per KROS's latest filing, from -$25.0 million in the prior quarter.
• Across five years, EBT topped out at $158.5 million in Q1 2025 and bottomed at -$53.0 million in Q3 2024.
• Historically, EBT has averaged -$23.4 million across 5 years, with a median of -$32.9 million in 2025.
• The sharpest annual moves came in 2022 and 2025: EBT sank 501.46% in 2022, then soared 467.62% in 2025.
• Over 5 years, EBT stood at -$29.7 million in 2022, then slumped by 56.32% to -$46.5 million in 2023, then gained by 1.57% to -$45.7 million in 2024, then surged by 45.38% to -$25.0 million in 2025, then slipped by 14.95% to -$28.7 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$28.7 million, -$25.0 million, and -$8.7 million for Q2 2026, Q4 2025, and Q3 2025 respectively.